Department of Urology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India.
Indian J Pharmacol. 2020 Jan-Feb;52(1):6-9. doi: 10.4103/ijp.IJP_545_18. Epub 2020 Mar 11.
Lower urinary tract symptoms (LUTS) in perimenopausal females are very common. It can be treated with alpha-blockers or application of topical oestrogen. The purpose of this study is to compare the efficacy of alpha-blockers versus topical estrogen in the treatment of LUTS in perimenopausal females.
All perimenopausal females between the age group of 45 and 60 years who present with the symptom of voiding LUTS were divided into two groups. Acute urinary retention patients were excluded from the study. The first group was given alpha-blocker (tamsulosin) and other group was given topical estrogen application (0.5%-1%) in the periurethral region. Patients were followed up clinically by voiding components of the International Prostate Symptom Score and objectively by uroflowmetry and postvoid residual (PVR) urine estimation (ultrasonography).
Alpha-blocker group had 40 females and topical estrogen group had 40 females. During the 6-week period, 8 patients of the first group and 6 patients of the estrogen group discontinued the treatment. In the first group, pretreatment mean Qmax (maximum flow rate) of patients was 7.2 ml/s and posttreatment Qmax was 18.4. In the second group, the values were 7.4 ml/s and 10.2, respectively. This difference was statistically significant ( < 0.0001). In the first group, pretreatment PVR urine was significant, which became insignificant after the treatment, whereas in the second group, PVR was significant posttreatment also.
Alpha-1a blockers should be used as the first-line medical management in perimenopausal females with symptoms of LUTS, as they have a clear advantage over topical estrogens.
围绝经期女性下尿路症状(LUTS)非常常见。可采用α受体阻滞剂或局部雌激素治疗。本研究旨在比较α受体阻滞剂与局部雌激素治疗围绝经期女性 LUTS 的疗效。
所有年龄在 45 至 60 岁之间出现排尿 LUTS 症状的围绝经期女性均分为两组。排除急性尿潴留患者。第一组给予α受体阻滞剂(坦索罗辛),另一组给予尿道周围局部雌激素应用(0.5%-1%)。通过国际前列腺症状评分的排尿成分以及尿流率和剩余尿量(PVR)的客观测量对患者进行临床随访(超声)。
α受体阻滞剂组有 40 名女性,局部雌激素组有 40 名女性。在 6 周的治疗期间,第一组有 8 名患者和雌激素组有 6 名患者停止治疗。在第一组中,治疗前患者的平均最大尿流率(Qmax)为 7.2ml/s,治疗后 Qmax 为 18.4ml/s。在第二组中,相应的值分别为 7.4ml/s 和 10.2ml/s。这种差异具有统计学意义(<0.0001)。在第一组中,治疗前 PVR 尿液明显,治疗后不再明显,而在第二组中,治疗后 PVR 仍然明显。
对于有 LUTS 症状的围绝经期女性,α-1a 受体阻滞剂应作为一线医学治疗方法,因为其具有明显优于局部雌激素的优势。